Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting

This article was originally published in RPM Report

Executive Summary

FDA has essentially shut down Ranbaxy’s three-year-old facility at Mohali as a source for products for the US market. But Ranbaxy is not alone among Indian firms in its quality product disputes with the agency. There is a significant uptick in activity by FDA in the region in what appears to be a period of intense culturization for the Indian firms into the ways FDA enforces cGMPs and handles on-site inspections.

You may also be interested in...



FDA Reassures Patients Of Generic Drug Quality Amid Questions In Media Analysis

Commissioner Scott Gottlieb and CDER Director Janet Woodcock say in joint statement that patients can be confident generics are safe and effective and recent media reports misinterpreted inspection and other data when suggesting the contrary.

FDA Vs. The Three-Second Rule

FDA’s crackdown on Indian manufacturing facilities continues four years after FDASIA boosted overseas inspection reports. The Warning Letters continue to paint an unflattering picture of practices at some sites.

GDUFA II Negotiations: Let the Saber-Rattling Begin

The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS081062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel